Abstract:The pool of microbes inhabiting our body is known as "microbiota" and their collective genomes as "microbiome". The colon is the most densely populated organ in the human body, although other parts, such as the skin, vaginal mucosa, or respiratory tract, also harbour specific microbiota. This microbial community regulates some important metabolic and physiological functions of the host, and drives the maturation of the immune system in early life, contributing to its homeostasis during life. Alterations of the intestinal microbiota can occur by changes in composition (dysbiosis), function, or microbiota-host interactions and they can be directly correlated with several diseases. The only disease in which a clear causal role of a dysbiotic microbiota has been demonstrated is the case of Clostridium difficile infections. Nonetheless, alterations in composition and function of the microbiota have been associated with several gastrointestinal diseases (inflammatory bowel disease, colorectal cancer, or irritable bowel syndrome), as well as extra-intestinal pathologies, such as those affecting the liver, or the respiratory tract (e.g., allergy, bronchial asthma, and cystic fibrosis), among others. Species of Bifidobacterium genus are the normal inhabitants of a healthy human gut and alterations in number and composition of their populations is one of the most frequent features present in these diseases. The use of probiotics, including bifidobacteria strains, in preventive medicine to maintain a healthy intestinal function is well documented. Probiotics are also proposed as therapeutic agents for gastrointestinal disorders and other pathologies. The World Gastroenterology Organization recently published potential clinical applications for several probiotic formulations, in which species of lactobacilli are predominant. This review is focused on probiotic preparations containing Bifidobacterium strains, alone or in combination with other bacteria, which have been tested in human clinical studies. In spite of extensive literature on and research into this topic, the degree of scientific evidence of the effectiveness of probiotics is still insufficient in most cases. More effort need to be made to design and conduct accurate human studies demonstrating the efficacy of probiotics in the prevention, alleviation, or treatment of different pathologies.

Bifidobacterium mechanisms of immune modulation and tolerance

Inhibitory effect of Bifidobacterium bifidum ATCC 29521 on colitis and its mechanism

Intestinal Immune Tolerance Mechanism of Symbiotic Microorganisms

Microbial interactions and the homeostasis of the gut microbiome: the role of Bifidobacterium

Immunomodulation by commensal and probiotic bacteria

The gut ecosystem and immune tolerance

Functional modulation of human intestinal epithelial cell responses by Bifidobacterium infantis and Lactobacillus salivarius

Intestinal microbiota in health and disease: Role of bifidobacteria in gut homeostasis

The Gut Core Microbial Species Bifidobacterium Longum: Colonization, Mechanisms, and Health Benefits

Probiotic Modulation of Innate Cell Pathogen Sensing and Signaling Events

Genomics and ecological overview of the genus Bifidobacterium

Antimicrobial and Immunomodulatory Effects of Bifidobacterium Strains: A Review

Potential Immunomodulatory Activity of a Selected Strain Bifidobacterium bifidum H3-R2 as Evidenced in vitro and in Immunosuppressed Mice

Molecular cross-talk among human intestinal bifidobacteria as explored by a human gut model

Commensal bacteria promote type I interferon signaling to maintain immune tolerance in mice

Symbiotic Firmicutes establish mutualism with the host via innate tolerance and resistance to control systemic immunity

Bifidobacterium spp. as functional foods: A review of current status, challenges, and strategies

Gut-Microbiota-Derived Metabolites Maintain Gut and Systemic Immune Homeostasis

An expanding stage for commensal microbes in host immune regulation

Exploring Bacteroidetes: Metabolic key points and immunological tricks of our gut commensals

<i>Bifidobacterium bifidum</i> H3-R2 and Its Molecular Communication within the Context of Ulcerative Colitis